Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANVIRAL intratumoral ORCA-010 in metastatic pancreatic cancer
NL-OMON61714Phase 1Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2027
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad5-D24RGD in pancreatic cancer (PC), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary endpoint(s). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON61714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61714.